Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

DIPSS Prognosis Score Questions: 1 - 17

Specify the maximum DIPSS score the patient ever achieved:1

Specify when maximum DIPSS score was documented2

At diagnosis

Between diagnosis and the preparative regimen

At last evaluation prior to the start of the preparative regimen

WBC

Known Unknown

3

4 x 109/L (x 103/mm3)

x 106/L

Date sample collected:5 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

6

7 g/dL g/L mmol/L

Date sample collected:8 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

9

Platelets

Known Unknown

10

11 x 109/L (x 103/mm3)

x 106/L

Date sample collected:12 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

13

Blasts in blood

Known Unknown

14

15 %

Date sample collected:16 __ __ __ __ - __ __- __ __

Did the recipient have constitutional symptoms? (> 10% weight loss in 6 months, night sweats, unexplained fever higher than 37.5°C)

Yes No

17

Pre-HCT JAK1 and JAK2 Inhibitor Therapy Questions: 18 - 33

Did the recipient receive JAK1 or JAK2 inhibitor therapy? (pre-HCT)

Yes No

18

Pre-HCT JAK1 and JAK2 Inhibitor Therapy (1) Questions: 19 - 31

Ruxolitinib (Jakafi)

yes no

19

Date therapy started

Known Unknown

20

Date started:21 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

22

Date stopped:23 __ __ __ __ - __ __- __ __

Specify the reason therapy stopped24

Toxicity (e.g.cytopenisa)

Not tolerable

Lack of response

Disease progression

Other

Unknown

Specify other reason:25

Other JAK1 or JAK2 inhibitor

Yes No

26

Specify other JAK1 or JAK2 inhibitor:27

Date therapy started

Known Unknown

28

Date started:29 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

30

Date stopped:31 __ __ __ __ - __ __- __ __

Response to therapy32

Clinical
improvement

: defined as 50% improvement in palpable spleen length for spleen palpable by 10 cm, or complete resolution of splenomegaly for palpable spleen
<10 cm

Stable disease

Non-splenic disease
progression

: increase in blasts to 10% to 19%, intolerance to treatment due to hematologic/non-hematologic side effects, or new onset transfusion-
requiring anemia

Splenic
disease
progression

: appearance of new splenomegaly palpable 5 cm below costal margin (BCM) or 100% increase in palpable distance BCM for baseline splenomegaly of 5 cm
to 10 cm BCM, 50% increase in palpable distance BCM for baseline splenomegaly of 10 cm BCM, loss of spleen response, or symptomatic splenomegaly
requiring splenectomy

Transformation to leukemia : peripheral blood or bone marrow blast count of 20%

Date assessed:33 __ __ __ __ - __ __- __ __

Laboratory Studies Prior to Therapy Questions: 34 - 71

Was presence of somatic mutations tested? (immediately prior to JAK2 inhibitor therapy initiation)

Yes No Unknown

34

Date sample collected:35 __ __ __ __ - __ __- __ __

Specify the cell source

Bone marrow Peripheral blood

36

JAK 2

Positive Negative Not done

37

CALR1

Positive Negative Not done

38

CALR2

Positive Negative Not done

39

MPL

Positive Negative Not done

40

ASXL1

Positive Negative Not done

41

SRSF2

Positive Negative Not done

42

EZH2

Positive Negative Not Done

43

IDH1

Positive Negative Not done

44

IDH2

Positive Negative Not done

45

LNK

Positive Negative Not done

46

CBL

Positive Negative Not done

47

TET2

Positive Negative Not done

48

IKZF1

Positive Negative Not done

49

DNMT3A

Positive Negative Not done

50

TP53

Positive Negative Not done

51

SF3B1

Positive Negative Not done

52

U2AF1

Positive Negative Not done

53

FLT3

Positive Negative Not done

54

Laboratory Studies Prior to Therapy (1) Questions: 55 - 56

Other gene mutation

Positive Negative Not done

55

Specify other gene mutation:56

WBC

Known Unknown

57

58 x 109/L (x 103/mm3)

x 106/L

Date sample collected:59 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

60

61 g/dL g/L mmol/L

Date sample collected:62 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

63

Platelets

Known Unknown

64

65 x 109/L (x 103/mm3)

x 106/L

Date sample collected:66 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

67

Blasts in blood

Known Unknown

68

69 %

Date sample collected:70 __ __ __ __ - __ __- __ __

Did the recipient have constitutional symptoms? (> 10% weight loss in 6 months, night sweats, unexplained fever higher than 37.5°C)

Yes No

71

Laboratory Studies at Last Evaluation Prior to HCT Questions: 72 - 76

Total serum ferritin

Known Unknown

72

73 ng/mL (µg/L)

Date sample collected:74 __ __ __ __ - __ __- __ __

CD34+ cells (peripheral blood)

Known Unknown

75

76 x 10

Disease Assessment at the Time of HCT Questions: 77 - 90

Did the recipient have evidence of pulmonary hypertension at HCT?

Yes No Unknown

77

Did the recipient have evidence of portal hypertension at HCT?

Yes No Unknown

78

Hepatomegaly

yes no

79

Specify the liver size:80 centimeters below right costal margin

Specify the method used to measure liver size:

Physical assessment Ultrasound CT

81

Spleen size82

Known

Unknown

Not applicable (splenectomy)

Specify the spleen size:83 centimeters below right costal margin

Iron overload

Yes No

84

Serum ferritin

Yes No

85

Liver MRI

Yes No

86

Other method

Yes No

87

Specify other method:88

Iron chelation therapy

Yes No

89

Phlebotomy

Yes No

90

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Report the clinical and laboratory assessments used to determine the maximum DIPSS score:

Specify therapy given:

Specify the laboratory values immediately prior to JAK1 / JAK2 inhibitor therapy.  If no JAK1 / JAK2 inhibitor therapy was given, report results at last evaluation prior to the start
of the preparative regimen:

Specify if the recipient had any of the following at the time of HCT:

Indicate how the iron overload diagnosis was made:

Specify therapy given for iron overload:

Center: CRID: 

Form 2556 R1.0: Myelofibrosis CMS Study Supplemental Pre-HCT Data

CIBMTR Form 2556 revision 1.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 4



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

DIPSS Prognosis Score Questions: 1 - 17

Specify the maximum DIPSS score the patient ever achieved:1

Specify when maximum DIPSS score was documented2

At diagnosis

Between diagnosis and the preparative regimen

At last evaluation prior to the start of the preparative regimen

WBC

Known Unknown

3

4 x 109/L (x 103/mm3)

x 106/L

Date sample collected:5 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

6

7 g/dL g/L mmol/L

Date sample collected:8 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

9

Platelets

Known Unknown

10

11 x 109/L (x 103/mm3)

x 106/L

Date sample collected:12 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

13

Blasts in blood

Known Unknown

14

15 %

Date sample collected:16 __ __ __ __ - __ __- __ __

Did the recipient have constitutional symptoms? (> 10% weight loss in 6 months, night sweats, unexplained fever higher than 37.5°C)

Yes No

17

Pre-HCT JAK1 and JAK2 Inhibitor Therapy Questions: 18 - 33

Did the recipient receive JAK1 or JAK2 inhibitor therapy? (pre-HCT)

Yes No

18

Pre-HCT JAK1 and JAK2 Inhibitor Therapy (1) Questions: 19 - 31

Ruxolitinib (Jakafi)

yes no

19

Date therapy started

Known Unknown

20

Date started:21 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

22

Date stopped:23 __ __ __ __ - __ __- __ __

Specify the reason therapy stopped24

Toxicity (e.g.cytopenisa)

Not tolerable

Lack of response

Disease progression

Other

Unknown

Specify other reason:25

Other JAK1 or JAK2 inhibitor

Yes No

26

Specify other JAK1 or JAK2 inhibitor:27

Date therapy started

Known Unknown

28

Date started:29 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

30

Date stopped:31 __ __ __ __ - __ __- __ __

Response to therapy32

Clinical
improvement

: defined as 50% improvement in palpable spleen length for spleen palpable by 10 cm, or complete resolution of splenomegaly for palpable spleen
<10 cm

Stable disease

Non-splenic disease
progression

: increase in blasts to 10% to 19%, intolerance to treatment due to hematologic/non-hematologic side effects, or new onset transfusion-
requiring anemia

Splenic
disease
progression

: appearance of new splenomegaly palpable 5 cm below costal margin (BCM) or 100% increase in palpable distance BCM for baseline splenomegaly of 5 cm
to 10 cm BCM, 50% increase in palpable distance BCM for baseline splenomegaly of 10 cm BCM, loss of spleen response, or symptomatic splenomegaly
requiring splenectomy

Transformation to leukemia : peripheral blood or bone marrow blast count of 20%

Date assessed:33 __ __ __ __ - __ __- __ __

Laboratory Studies Prior to Therapy Questions: 34 - 71

Was presence of somatic mutations tested? (immediately prior to JAK2 inhibitor therapy initiation)

Yes No Unknown

34

Date sample collected:35 __ __ __ __ - __ __- __ __

Specify the cell source

Bone marrow Peripheral blood

36

JAK 2

Positive Negative Not done

37

CALR1

Positive Negative Not done

38

CALR2

Positive Negative Not done

39

MPL

Positive Negative Not done

40

ASXL1

Positive Negative Not done

41

SRSF2

Positive Negative Not done

42

EZH2

Positive Negative Not Done

43

IDH1

Positive Negative Not done

44

IDH2

Positive Negative Not done

45

LNK

Positive Negative Not done

46

CBL

Positive Negative Not done

47

TET2

Positive Negative Not done

48

IKZF1

Positive Negative Not done

49

DNMT3A

Positive Negative Not done

50

TP53

Positive Negative Not done

51

SF3B1

Positive Negative Not done

52

U2AF1

Positive Negative Not done

53

FLT3

Positive Negative Not done

54

Laboratory Studies Prior to Therapy (1) Questions: 55 - 56

Other gene mutation

Positive Negative Not done

55

Specify other gene mutation:56

WBC

Known Unknown

57

58 x 109/L (x 103/mm3)

x 106/L

Date sample collected:59 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

60

61 g/dL g/L mmol/L

Date sample collected:62 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

63

Platelets

Known Unknown

64

65 x 109/L (x 103/mm3)

x 106/L

Date sample collected:66 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

67

Blasts in blood

Known Unknown

68

69 %

Date sample collected:70 __ __ __ __ - __ __- __ __

Did the recipient have constitutional symptoms? (> 10% weight loss in 6 months, night sweats, unexplained fever higher than 37.5°C)

Yes No

71

Laboratory Studies at Last Evaluation Prior to HCT Questions: 72 - 76

Total serum ferritin

Known Unknown

72

73 ng/mL (µg/L)

Date sample collected:74 __ __ __ __ - __ __- __ __

CD34+ cells (peripheral blood)

Known Unknown

75

76 x 10

Disease Assessment at the Time of HCT Questions: 77 - 90

Did the recipient have evidence of pulmonary hypertension at HCT?

Yes No Unknown

77

Did the recipient have evidence of portal hypertension at HCT?

Yes No Unknown

78

Hepatomegaly

yes no

79

Specify the liver size:80 centimeters below right costal margin

Specify the method used to measure liver size:

Physical assessment Ultrasound CT

81

Spleen size82

Known

Unknown

Not applicable (splenectomy)

Specify the spleen size:83 centimeters below right costal margin

Iron overload

Yes No

84

Serum ferritin

Yes No

85

Liver MRI

Yes No

86

Other method

Yes No

87

Specify other method:88

Iron chelation therapy

Yes No

89

Phlebotomy

Yes No

90

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Report the clinical and laboratory assessments used to determine the maximum DIPSS score:

Specify therapy given:

Specify the laboratory values immediately prior to JAK1 / JAK2 inhibitor therapy.  If no JAK1 / JAK2 inhibitor therapy was given, report results at last evaluation prior to the start
of the preparative regimen:

Specify if the recipient had any of the following at the time of HCT:

Indicate how the iron overload diagnosis was made:

Specify therapy given for iron overload:

Center: CRID: 

Form 2556 R1.0: Myelofibrosis CMS Study Supplemental Pre-HCT Data

CIBMTR Form 2556 revision 1.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 4



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

DIPSS Prognosis Score Questions: 1 - 17

Specify the maximum DIPSS score the patient ever achieved:1

Specify when maximum DIPSS score was documented2

At diagnosis

Between diagnosis and the preparative regimen

At last evaluation prior to the start of the preparative regimen

WBC

Known Unknown

3

4 x 109/L (x 103/mm3)

x 106/L

Date sample collected:5 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

6

7 g/dL g/L mmol/L

Date sample collected:8 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

9

Platelets

Known Unknown

10

11 x 109/L (x 103/mm3)

x 106/L

Date sample collected:12 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

13

Blasts in blood

Known Unknown

14

15 %

Date sample collected:16 __ __ __ __ - __ __- __ __

Did the recipient have constitutional symptoms? (> 10% weight loss in 6 months, night sweats, unexplained fever higher than 37.5°C)

Yes No

17

Pre-HCT JAK1 and JAK2 Inhibitor Therapy Questions: 18 - 33

Did the recipient receive JAK1 or JAK2 inhibitor therapy? (pre-HCT)

Yes No

18

Pre-HCT JAK1 and JAK2 Inhibitor Therapy (1) Questions: 19 - 31

Ruxolitinib (Jakafi)

yes no

19

Date therapy started

Known Unknown

20

Date started:21 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

22

Date stopped:23 __ __ __ __ - __ __- __ __

Specify the reason therapy stopped24

Toxicity (e.g.cytopenisa)

Not tolerable

Lack of response

Disease progression

Other

Unknown

Specify other reason:25

Other JAK1 or JAK2 inhibitor

Yes No

26

Specify other JAK1 or JAK2 inhibitor:27

Date therapy started

Known Unknown

28

Date started:29 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

30

Date stopped:31 __ __ __ __ - __ __- __ __

Response to therapy32

Clinical
improvement

: defined as 50% improvement in palpable spleen length for spleen palpable by 10 cm, or complete resolution of splenomegaly for palpable spleen
<10 cm

Stable disease

Non-splenic disease
progression

: increase in blasts to 10% to 19%, intolerance to treatment due to hematologic/non-hematologic side effects, or new onset transfusion-
requiring anemia

Splenic
disease
progression

: appearance of new splenomegaly palpable 5 cm below costal margin (BCM) or 100% increase in palpable distance BCM for baseline splenomegaly of 5 cm
to 10 cm BCM, 50% increase in palpable distance BCM for baseline splenomegaly of 10 cm BCM, loss of spleen response, or symptomatic splenomegaly
requiring splenectomy

Transformation to leukemia : peripheral blood or bone marrow blast count of 20%

Date assessed:33 __ __ __ __ - __ __- __ __

Laboratory Studies Prior to Therapy Questions: 34 - 71

Was presence of somatic mutations tested? (immediately prior to JAK2 inhibitor therapy initiation)

Yes No Unknown

34

Date sample collected:35 __ __ __ __ - __ __- __ __

Specify the cell source

Bone marrow Peripheral blood

36

JAK 2

Positive Negative Not done

37

CALR1

Positive Negative Not done

38

CALR2

Positive Negative Not done

39

MPL

Positive Negative Not done

40

ASXL1

Positive Negative Not done

41

SRSF2

Positive Negative Not done

42

EZH2

Positive Negative Not Done

43

IDH1

Positive Negative Not done

44

IDH2

Positive Negative Not done

45

LNK

Positive Negative Not done

46

CBL

Positive Negative Not done

47

TET2

Positive Negative Not done

48

IKZF1

Positive Negative Not done

49

DNMT3A

Positive Negative Not done

50

TP53

Positive Negative Not done

51

SF3B1

Positive Negative Not done

52

U2AF1

Positive Negative Not done

53

FLT3

Positive Negative Not done

54

Laboratory Studies Prior to Therapy (1) Questions: 55 - 56

Other gene mutation

Positive Negative Not done

55

Specify other gene mutation:56

WBC

Known Unknown

57

58 x 109/L (x 103/mm3)

x 106/L

Date sample collected:59 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

60

61 g/dL g/L mmol/L

Date sample collected:62 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

63

Platelets

Known Unknown

64

65 x 109/L (x 103/mm3)

x 106/L

Date sample collected:66 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

67

Blasts in blood

Known Unknown

68

69 %

Date sample collected:70 __ __ __ __ - __ __- __ __

Did the recipient have constitutional symptoms? (> 10% weight loss in 6 months, night sweats, unexplained fever higher than 37.5°C)

Yes No

71

Laboratory Studies at Last Evaluation Prior to HCT Questions: 72 - 76

Total serum ferritin

Known Unknown

72

73 ng/mL (µg/L)

Date sample collected:74 __ __ __ __ - __ __- __ __

CD34+ cells (peripheral blood)

Known Unknown

75

76 x 10

Disease Assessment at the Time of HCT Questions: 77 - 90

Did the recipient have evidence of pulmonary hypertension at HCT?

Yes No Unknown

77

Did the recipient have evidence of portal hypertension at HCT?

Yes No Unknown

78

Hepatomegaly

yes no

79

Specify the liver size:80 centimeters below right costal margin

Specify the method used to measure liver size:

Physical assessment Ultrasound CT

81

Spleen size82

Known

Unknown

Not applicable (splenectomy)

Specify the spleen size:83 centimeters below right costal margin

Iron overload

Yes No

84

Serum ferritin

Yes No

85

Liver MRI

Yes No

86

Other method

Yes No

87

Specify other method:88

Iron chelation therapy

Yes No

89

Phlebotomy

Yes No

90

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Report the clinical and laboratory assessments used to determine the maximum DIPSS score:

Specify therapy given:

Specify the laboratory values immediately prior to JAK1 / JAK2 inhibitor therapy.  If no JAK1 / JAK2 inhibitor therapy was given, report results at last evaluation prior to the start
of the preparative regimen:

Specify if the recipient had any of the following at the time of HCT:

Indicate how the iron overload diagnosis was made:

Specify therapy given for iron overload:

Center: CRID: 

Form 2556 R1.0: Myelofibrosis CMS Study Supplemental Pre-HCT Data

CIBMTR Form 2556 revision 1.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 4



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

DIPSS Prognosis Score Questions: 1 - 17

Specify the maximum DIPSS score the patient ever achieved:1

Specify when maximum DIPSS score was documented2

At diagnosis

Between diagnosis and the preparative regimen

At last evaluation prior to the start of the preparative regimen

WBC

Known Unknown

3

4 x 109/L (x 103/mm3)

x 106/L

Date sample collected:5 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

6

7 g/dL g/L mmol/L

Date sample collected:8 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

9

Platelets

Known Unknown

10

11 x 109/L (x 103/mm3)

x 106/L

Date sample collected:12 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

13

Blasts in blood

Known Unknown

14

15 %

Date sample collected:16 __ __ __ __ - __ __- __ __

Did the recipient have constitutional symptoms? (> 10% weight loss in 6 months, night sweats, unexplained fever higher than 37.5°C)

Yes No

17

Pre-HCT JAK1 and JAK2 Inhibitor Therapy Questions: 18 - 33

Did the recipient receive JAK1 or JAK2 inhibitor therapy? (pre-HCT)

Yes No

18

Pre-HCT JAK1 and JAK2 Inhibitor Therapy (1) Questions: 19 - 31

Ruxolitinib (Jakafi)

yes no

19

Date therapy started

Known Unknown

20

Date started:21 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

22

Date stopped:23 __ __ __ __ - __ __- __ __

Specify the reason therapy stopped24

Toxicity (e.g.cytopenisa)

Not tolerable

Lack of response

Disease progression

Other

Unknown

Specify other reason:25

Other JAK1 or JAK2 inhibitor

Yes No

26

Specify other JAK1 or JAK2 inhibitor:27

Date therapy started

Known Unknown

28

Date started:29 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

30

Date stopped:31 __ __ __ __ - __ __- __ __

Response to therapy32

Clinical
improvement

: defined as 50% improvement in palpable spleen length for spleen palpable by 10 cm, or complete resolution of splenomegaly for palpable spleen
<10 cm

Stable disease

Non-splenic disease
progression

: increase in blasts to 10% to 19%, intolerance to treatment due to hematologic/non-hematologic side effects, or new onset transfusion-
requiring anemia

Splenic
disease
progression

: appearance of new splenomegaly palpable 5 cm below costal margin (BCM) or 100% increase in palpable distance BCM for baseline splenomegaly of 5 cm
to 10 cm BCM, 50% increase in palpable distance BCM for baseline splenomegaly of 10 cm BCM, loss of spleen response, or symptomatic splenomegaly
requiring splenectomy

Transformation to leukemia : peripheral blood or bone marrow blast count of 20%

Date assessed:33 __ __ __ __ - __ __- __ __

Laboratory Studies Prior to Therapy Questions: 34 - 71

Was presence of somatic mutations tested? (immediately prior to JAK2 inhibitor therapy initiation)

Yes No Unknown

34

Date sample collected:35 __ __ __ __ - __ __- __ __

Specify the cell source

Bone marrow Peripheral blood

36

JAK 2

Positive Negative Not done

37

CALR1

Positive Negative Not done

38

CALR2

Positive Negative Not done

39

MPL

Positive Negative Not done

40

ASXL1

Positive Negative Not done

41

SRSF2

Positive Negative Not done

42

EZH2

Positive Negative Not Done

43

IDH1

Positive Negative Not done

44

IDH2

Positive Negative Not done

45

LNK

Positive Negative Not done

46

CBL

Positive Negative Not done

47

TET2

Positive Negative Not done

48

IKZF1

Positive Negative Not done

49

DNMT3A

Positive Negative Not done

50

TP53

Positive Negative Not done

51

SF3B1

Positive Negative Not done

52

U2AF1

Positive Negative Not done

53

FLT3

Positive Negative Not done

54

Laboratory Studies Prior to Therapy (1) Questions: 55 - 56

Other gene mutation

Positive Negative Not done

55

Specify other gene mutation:56

WBC

Known Unknown

57

58 x 109/L (x 103/mm3)

x 106/L

Date sample collected:59 __ __ __ __ - __ __- __ __

Hemoglobin

Known Unknown

60

61 g/dL g/L mmol/L

Date sample collected:62 __ __ __ __ - __ __- __ __

Was RBC transfused ≤ 30 days before date of test?

Yes No

63

Platelets

Known Unknown

64

65 x 109/L (x 103/mm3)

x 106/L

Date sample collected:66 __ __ __ __ - __ __- __ __

Were platelets transfused ≤ 7 days before date of test?

Yes No

67

Blasts in blood

Known Unknown

68

69 %

Date sample collected:70 __ __ __ __ - __ __- __ __

Did the recipient have constitutional symptoms? (> 10% weight loss in 6 months, night sweats, unexplained fever higher than 37.5°C)

Yes No

71

Laboratory Studies at Last Evaluation Prior to HCT Questions: 72 - 76

Total serum ferritin

Known Unknown

72

73 ng/mL (µg/L)

Date sample collected:74 __ __ __ __ - __ __- __ __

CD34+ cells (peripheral blood)

Known Unknown

75

76 x 10

Disease Assessment at the Time of HCT Questions: 77 - 90

Did the recipient have evidence of pulmonary hypertension at HCT?

Yes No Unknown

77

Did the recipient have evidence of portal hypertension at HCT?

Yes No Unknown

78

Hepatomegaly

yes no

79

Specify the liver size:80 centimeters below right costal margin

Specify the method used to measure liver size:

Physical assessment Ultrasound CT

81

Spleen size82

Known

Unknown

Not applicable (splenectomy)

Specify the spleen size:83 centimeters below right costal margin

Iron overload

Yes No

84

Serum ferritin

Yes No

85

Liver MRI

Yes No

86

Other method

Yes No

87

Specify other method:88

Iron chelation therapy

Yes No

89

Phlebotomy

Yes No

90

First Name: Last Name:

E-mail address: Date: __ __ __ __ - __ __- __ __

HCT type: (check all that apply)

Product type: (check all that apply)

Report the clinical and laboratory assessments used to determine the maximum DIPSS score:

Specify therapy given:

Specify the laboratory values immediately prior to JAK1 / JAK2 inhibitor therapy.  If no JAK1 / JAK2 inhibitor therapy was given, report results at last evaluation prior to the start
of the preparative regimen:

Specify if the recipient had any of the following at the time of HCT:

Indicate how the iron overload diagnosis was made:

Specify therapy given for iron overload:

Center: CRID: 

Form 2556 R1.0: Myelofibrosis CMS Study Supplemental Pre-HCT Data

CIBMTR Form 2556 revision 1.0 last updated January 2017 
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 4